Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

comunicati

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

26.03.2020 - 07:45

0

SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis

Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe

SEATTLE and BRISBANE, Australia, March 26, 2020 /PRNewswire/ -- Immunexpress, Inc. a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced it has received CE Marking of SeptiCyte® RAPID for its host response technology. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla™ platform, providing actionable results in about one hour to guide the physician to optimize patient management decisions.

The CE Marking of SeptiCyte® RAPID is a significant accomplishment for Immunexpress, enabling the company to market and sell the near-patient sample-to-answer test in European Union (EU) member countries and those  harmonized with the EU IVD Directive (98/79/EC). Immunexpress plans to immediately initiate commercial operations in Europe, and announced a long-term commercialization partnership with Biocartis NV, an industry leader in the molecular diagnostic space. Biocartis currently has over 1,300 Idylla™ instruments installed throughout the world.  

"Achieving the CE IVD registration and entering commercialization of Immunexpress' leading host response SeptiCyte technology represents a new and exciting phase for our company," said Rolland Carlson, Ph.D., Chief Executive Officer of Immunexpress. "We believe Biocartis, with its well established and growing customer base, will be highly effective in delivering to the European community a new and novel sepsis diagnostic tool, designed to enhance the certainty of early and rapid sepsis diagnosis, to improve clinical outcomes and to lower healthcare costs."

The ongoing COVID-19 pandemic underscores the unmet need for technologies that efficiently discriminate patients with mild infection from those that may develop serious complications related to sepsis, especially when critical medical resources are in short supply. In a recent study of the risk factors associated with COVID-19 mortality, sepsis was the most frequently observed complication1. The early diagnosis of bacterial and viral sepsis with SeptiCyte® RAPID, including the immediate and overwhelming global need to triage COVID-19 patients with worsening prognoses, will ensure rapid initiation of sepsis management protocols increasing the potential to save lives.

Dr. Carlson continued, "Together with Biocartis, Immunexpress is committed to mitigating the constraints on hospitals that are affected by the COVID-19 pandemic. We are urgently working towards improving patient outcomes by swiftly triaging COVID-19 patients to receive the most appropriate treatment. Accurate diagnostic testing of sepsis is more important now than ever to enable physicians to make rapid clinical decisions in resource-constrained ICUs."

About SeptiCyte® RAPID

SeptiCyte® RAPID is a gene expression assay using reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene® Blood RNA Tube. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte® RAPID generates a score (SeptiScore™) that falls within one of three discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla™ System.

About BiocartisBiocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

About ImmunexpressImmunexpress is a molecular diagnostic company, founded in Australian and based out of Seattle, Washington, USA, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's immune response by quantifying and analyzing gene expression signatures from whole blood, providing actionable results in about an hour to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis' Idylla™ platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis. This powerful combination of technologies enhances certainty for early sepsis diagnosis, to improve clinical outcomes and lower healthcare costs. For more information visit http://www.immunexpress.com/.

Follow Immunexpress on Twitter and LinkedIn.

*Immunexpress is licensed to use the Idylla™ trademark from Biocartis NV.

Media Contacts: Maggie BellerRusso Partners, LLC+1(646) 942-5631Maggie.beller@russopartnersllc.com

1Zhou, F., et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

Logo - https://mma.prnewswire.com/media/1033289/Immunexpress_Inc.jpg   

Condividi le tue opinioni su Corriere dell'Umbria

Caratteri rimanenti: 400

Più letti oggi

Mediagallery

Trump: "Oltre 100 mln di dollari in aiuti sanitari per l'Italia" SOTTOTITOLI

Trump: "Oltre 100 mln di dollari in aiuti sanitari per l'Italia" SOTTOTITOLI

(Agenzia Vista) Washington, 31 marzo 2020 Trump: "Oltre 100 mln di dollari in aiuti sanitari per l'Italia" SOTTOTITOLI Lo ha detto il Presidente USA Donald Trump nella tradizionale conferenza stampa quotidiana sul Covid-19 dalla Rose Garden alla Casa Bianca. In serata il presidente del Consiglio, Giuseppe Conte, ha avuto una "lunga e amichevole conversazione" con il Presidente degli Stati Uniti ...

 
Trump mostra la macchina per il test rapido in 5 minuti per cornavirus

Trump mostra la macchina per il test rapido in 5 minuti per cornavirus

(Agenzia Vista) Washington, 31 marzo 2020 Trump mostra macchina per il test rapido in 5 minuti per cornavirus Negli Stati Uniti sono stati effettuati oltre un milione di test sul coronavirus. Lo ha annunciato il presidente Donald Trump durante la conferenza stampa quotidiana sul Covid-19 sottolineando come «nessun altro Paese.«Spediremo ventilatori in Italia, in Francia, in Spagna», ha aggiunto. ...

 
Trump: Se seguiamo misure potremo salvare oltre 1 mln di vite americane, prossimi 30 giorni cruciali

Trump: Se seguiamo misure potremo salvare oltre 1 mln di vite americane, prossimi 30 giorni cruciali

(Agenzia Vista) Roma, 31 marzo 2020 Trump se seguiamo le misure potremo salvare oltre 1 mln di vite americane, prossimi 30 giorni cruciali Negli Stati Uniti sono stati effettuati oltre un milione di test sul coronavirus. Lo ha annunciato il presidente Donald Trump durante la conferenza stampa quotidiana sul Covid-19 sottolineando come «nessun altro Paese.«Spediremo ventilatori in Italia, in ...

 
Trump: Oltre 1 mln di americani testati per cornavirus

Trump: Oltre 1 mln di americani testati per cornavirus

(Agenzia Vista) Washington, 31 marzo 2020 Trump oltre 1 mln di americani testati per cornavirus Negli Stati Uniti sono stati effettuati oltre un milione di test sul coronavirus. Lo ha annunciato il presidente Donald Trump durante la conferenza stampa quotidiana sul Covid-19 sottolineando come «nessun altro Paese.«Spediremo ventilatori in Italia, in Francia, in Spagna», ha aggiunto. I Paesi che ...

 
Amici 2020 serale, l'esultanza dei finalisti dietro le quinte: Gaia, Giulia, Javier e Nicolai scatenati Video

Televisione

Amici 2020 serale, l'esultanza dei finalisti dietro le quinte: Gaia, Giulia, Javier e Nicolai scatenati Video

Amici 2020 serale, è al verdetto finale. Venerdì 3 aprile è in programma la finale del talent di Maria De Filippi e sarà trasmesso su Canale 5. La semifinale di venerdì ...

30.03.2020

Amici 2020 serale, Javier Rojas: proposta per Talisa spiazza tutti prima della finale. La reazione degli altri

Talent

Amici 2020 serale, Javier Rojas: proposta per Talisa spiazza tutti prima della finale. La reazione degli altri

Amici 2020 serale si avvia verso la finale di venerdì 3 aprile, in onda su Canale 5 e condotta da Maria De Filippi.  Sono quattro gli allievi che se la giocheranno e che si ...

30.03.2020

Eric Clapton, i 75 anni di una leggenda. Rinviati i concerti italiani a causa del Coronavirus

MUSICA

Video Eric Clapton, i 75 anni di una leggenda. Rinviati  i due concerti italiani

Il compleanno di una leggenda. Eric Clapton compie 75 anni e dovrà farlo senza concerti. Causa Coronavirus ha infatti dovuto rinviare il tour in Europa che comprendeva anche ...

30.03.2020